De novo purine synthesis enzymes (DNPS enzymes)

De novo purine synthesis enzymes comprise a multi-step metabolic pathway responsible for the synthesis of purine nucleotides, such as adenosine and guanosine, from simple precursor molecules like ribose-5-phosphate, amino acids, and carbon dioxide (StatPearls: Purine Metabolism, 2023). This pathway is essential for providing the building blocks required for DNA and RNA synthesis, energy metabolism (ATP/GTP), and intracellular signaling (NCBI: Purine Biosynthesis, 2022). In rapidly dividing cells, such as cancer cells and activated lymphocytes, the demand for purines is significantly increased, making these enzymes critical therapeutic targets (Nature Reviews Cancer: Nucleotide Metabolism, 2019). Drugs targeting this pathway, including antimetabolites like methotrexate and mycophenolate, work by inhibiting specific enzymes such as dihydrofolate reductase or inosine monophosphate dehydrogenase to deplete nucleotide pools and induce cell cycle arrest or apoptosis (DrugBank: Methotrexate). Beyond oncology, these enzymes are targeted in immunosuppressive therapy to prevent organ transplant rejection and treat autoimmune disorders (PubMed: Mycophenolate Mechanism, 2021). Recent research also highlights the formation of a multi-enzyme complex known as the purinosome to enhance pathway efficiency under metabolic stress (Science: The Purinosome, 2008).

Other names

Purine biosynthetic pathwayDe novo purine nucleotide synthesisPurinosomePurine de novo biosynthesis

Inhibition of specific rate-limiting enzymes within the de novo purine biosynthetic pathway, such as inosine monophosphate dehydrogenase (IMPDH), phosphoribosylpyrophosphate amidotransferase (PPAT), or glycinamide ribonucleotide transformylase (GART), leading to the depletion of intracellular purine nucleotide pools (ATP and GTP), which subsequently impairs DNA/RNA synthesis and cell division.